8UR-19440-80052
2 vaccinations
4 coded responses
15 check-ins
4 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 975 / OR
- Registered
- 2021-03-11
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-10
Dose 1 — Moderna
-
2021-03-11
Registered in v-safe
-
2021-03-11
Dose 2 — Moderna
- 2021-03-11
-
2021-03-12
Survey response — days 1–6 daily, dose 2MedDRA: Asthenia — Feeling: Poor · Site: Pain, Swelling · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Nausea, Diarrhea · Be unable to work, Be unable to do your normal daily activitiesFree text: WeaknessMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-13
-
2021-03-14
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-03-15
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain, Itching · Chills, Fatigue or tirednessAdult check-in
-
2021-03-17
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Chills, Headache, Fatigue or tirednessAdult check-in
-
2021-03-18
Health check-in — day 7, dose 2Feeling: Poor · Fever · Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
- 2021-03-25
- 2021-04-03
- 2021-04-08
-
2021-04-15
Survey response — day 35, dose 2MedDRA: Fatigue — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Intense fatigue. This very well may be caused by transitioning to in person teaching, with all of the replanning, adjusting, extra hours sanitizing, and policing I have to do of students now.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-22
- 2021-06-10
-
2021-09-09
Survey response — 6 months, dose 2MedDRA: Balance disorder, Confusional state, Fatigue, Muscle disorder, Nausea, Tinnitus, VIIIth nerve injury, Vertigo, Viral labyrinthitis, Vomiting — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: Viral labrynthitus - permanent damage to one vestibular nerve, resulting in loss of balance, tinitus, vertigo, nausea, vomiting, confusion, muscular problems in the neck, and fatigue.MedDRA releases: 2024-11 · check-in free text available
-
2021-09-09
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr1 call case(s)
- 2021-09-10
- 2021-09-13
-
2022-03-12
Survey response — 12 months, dose 2MedDRA: Delivery, Viral labyrinthitis — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, HospitalizationFree text: Gave birth. Recurring viral labrynthitusMedDRA releases: 2024-11 · check-in free text available
-
2022-03-12
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · Hospitalization · 1 call case(s)
- 2022-03-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-10 | Moderna | |
| 2 | 2021-03-11 | Moderna |
Call center
2 call center cases
2 unsuccessful
Free text
Release 5 — days 1–6 daily, dose 2
Systemic reaction (other): Weakness
Release 7 — day 35, dose 2
Symptoms: Intense fatigue. This very well may be caused by transitioning to in person teaching, with all of the replanning, adjusting, extra hours sanitizing, and policing I have to do of students now.
Release 9 — 6 months, dose 2
Symptoms: Viral labrynthitus - permanent damage to one vestibular nerve, resulting in loss of balance, tinitus, vertigo, nausea, vomiting, confusion, muscular problems in the neck, and fatigue.
Release 11 — 12 months, dose 2
Symptoms: Gave birth. Recurring viral labrynthitus
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Balance disorder | · | · | ✓ |
| SD | Confusional state | · | · | ✓ |
| SD | Delivery | · | · | ✓ |
| SD | Fatigue | ✓ | ✓ | ✓ |
| SD | Muscle disorder | · | · | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Tinnitus | · | · | ✓ |
| SD | Vertigo | · | · | ✓ |
| SD | VIIIth nerve injury | · | · | ✓ |
| SD | Viral labyrinthitis | · | · | ✓ |
| SD | Vomiting | · | · | ✓ |
| SRO | Asthenia | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release